MedTrace Logo

A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

NCT05564052 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-10-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to provide continued access to treatment for participants who continue to benefit from treatment.

Conditions

  • Lymphoma, Mantle-Cell

Interventions

DRUG

Ibrutinib

Ibrutinib capsules will be administered orally.

DRUG

Lenalidomide

Lenalidomide capsules will be administered orally.

DRUG

Rituximab

Rituximab will be administered IV.

DRUG

Bortezomib

Bortezomib will be administered either intravenously or subcutaneously.

Sponsors & Collaborators

  • Pharmacyclics LLC.

    collaborator INDUSTRY

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-06
Primary Completion
2023-12-06
Completion
2024-09-26
FDA Drug
Yes

Countries

  • Brazil
  • Czechia
  • Greece
  • India
  • Malaysia
  • Poland
  • Puerto Rico
  • Romania
  • Spain
  • Sweden
  • Taiwan
  • Thailand
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05564052 on ClinicalTrials.gov